Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- A Case report with updated review of literature
Nirmalya Banerjee; Devmalya Banerjee; Neha Choudhary
Abstract
Keywords
References
1 McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA. 1966;195(5):388-90.
2 Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast. 2012;21(3):350-3.
3 Li D, Xiao X, Yang W, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol. 2012;25(4):567-75.
4 Laé M, Fréneaux P, Sastre-Garau X, Chouchane O, Sigal-Zafrani B, Vincent-Salomon A. Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol. 2009;22(2):291-8.
5 Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011;135(12):1606-10.
6 Kozioł M, Püsküllüoglu M, Zygulska A. PARP inhibitors and their role in the therapy of triple-negative metastatic breast cancer. Przegl Lek. 2012;69(6):256-70. PMid:23094440.
7 Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
8 Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12(11):537-44.
9 Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016;2(1):1603.
10 Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-76.
11 Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.
12 Lijuan L, Nan W, Fangxuan L, Lingmei L, Lijuan W, Juntian L. Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma. Cancer Biol Med. 2019;16(1):139-46.
13 Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016;113(7):721-5.
14 Amott DH, Masters R, Moore S. Secretory carcinoma of the breast. Breast J. 2006;12(2):183.
15 Rosen PP, Cranor ML. Secretory carcinoma of the breast. Arch Pathol Lab Med. 1991;115(2):141-4. PMid:1992979.
16 Soyer T, Yaman Bajin İ, Orhan D, et al. Secretory breast carcinoma in a 6-year-old girl: mastectomy with sentinel lymph node dissection. Pediatr Surg Int. 2015;31(7):677-81.
17 Garlick JW, Olson KA, Downs-Kelly E, Bucher BT, Matsen CB. Secretory breast carcinoma in an 8-year-old girl: A case report and literature review. Breast J. 2018;24(6):1055-61.
18 Din NU, Idrees R, Fatima S, Kayani N. Secretory carcinoma of breast: clinicopathologic study of 8 cases. Ann Diagn Pathol. 2013;17(1):54-7.
19 Tognon C, Gamett M, Kenward E, Kay R, Morrison K, Sorensen PH. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3- kinase-Akt signaling for fibroblast transformation. Cancer Res. 2001;61(24):8909-16. PMid:11751416.
20 Strauss BL, Bratthauer GL, Tavassoli FA. STAT 5a expression in the breast is maintained in secretory carcinoma, in contrast to other histologic types. Hum Pathol. 2006;37(5):586-92.
21 Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-47.
22 Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-9.
23 Drilon A, Siena S, Ou SI, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400-9.
24 Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med. 2011;135(12):1606-10.
25 Lee SG, Jung SP, Lee HY, et al. Secretory breast carcinoma: A report of three cases and a review of the literature. Oncol Lett. 2014;8(2):683-6.
26 Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: case report and review of the literature. Ann Oncol. 2000;11(10):1343-7.
Submitted date:
05/30/2020
Accepted date:
08/12/2020
Publication date:
12/08/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email